Literature DB >> 10221455

Distribution of peptide transporter PEPT2 mRNA in the rat nervous system.

U V Berger1, M A Hediger.   

Abstract

The signaling action of neuropeptides in the brain is terminated by breakdown through extracellular peptidases and subsequent removal of the peptide fragments from the extracellular fluid via specific transporter proteins. Here we describe the anatomical distribution in the rat nervous system of the recently isolated high affinity peptide transporter PEPT2. Using nonisotopic in situ hybridization we demonstrate that PEPT2 mRNA is expressed in brain by astrocytes, subependymal cells, ependymal cells and epithelial cells of choroid plexus. Furthermore, PEPT2 is expressed in retina by Müller cells and in dorsal root ganglia by satellite cells. The mRNA levels of PEPT2 in astrocytes are moderate and relatively homogenous throughout the brain except for an area in ventral forebrain where PEPT2 levels are below average. PEPT2 mRNA expression is weakly upregulated in reactive astrocytes that were stimulated through an injection of the glutamatergic neurotoxin quinolinic acid. These data suggest that removal of neuropeptide fragments from brain extracellular fluid occurs via PEPT2 expressed in astrocytes, ependymal cells and choroid plexus epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221455     DOI: 10.1007/s004290050242

Source DB:  PubMed          Journal:  Anat Embryol (Berl)        ISSN: 0340-2061


  26 in total

1.  PEPT2-mediated uptake of neuropeptides in rat choroid plexus.

Authors:  N S Teuscher; R F Keep; D E Smith
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes.

Authors:  Scott M Ocheltree; Richard F Keep; Hong Shen; Dongli Yang; Bret A Hughes; David E Smith
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 3.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

4.  ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood--brain barrier cell line, hCMEC/D3 [corrected].

Authors:  Stephen M Carl; David J Lindley; Debanjan Das; Pierre O Couraud; Babette B Weksler; Ignacio Romero; Stephanie A Mowery; Gregory T Knipp
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 5.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung.

Authors:  D A Groneberg; P R Eynott; F Döring; Q Thai Dinh; T Oates; P J Barnes; K F Chung; H Daniel; A Fischer
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

7.  Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study.

Authors:  Xiaomei Chen; Richard F Keep; Yan Liang; Hao-Jie Zhu; Margareta Hammarlund-Udenaes; Yongjun Hu; David E Smith
Journal:  Biochem Pharmacol       Date:  2017-02-10       Impact factor: 5.858

Review 8.  Carnosine and homocarnosine, the forgotten, enigmatic peptides of the brain.

Authors:  Karl Bauer
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

Review 9.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

10.  Functional and molecular expression of the proton-coupled oligopeptide transporters in spleen and macrophages from mouse and human.

Authors:  Dongli Sun; Yuqing Wang; Fuqing Tan; Danbo Fang; Yongjun Hu; David E Smith; Huidi Jiang
Journal:  Mol Pharm       Date:  2013-03-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.